Aggrecanases from the ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) family are important therapeutic targets due to their essential role in aggrecan depletion in arthritic diseases. Whether their function is also important for matrix rearrangements during chondrogenesis and thus, cartilage regeneration, is however so far unknown. The aim of this study was to analyse the expression and function of ADAMTS with aggrecanase activity during chondrogenic differentiation of human mesenchymal stem cells (MSCs). Chondrogenic differentiation was induced in bone marrow-derived MSC pellets and expression of COL2A1, aggrecan, ADAMTS1, 4, 5, 9, 16 and furin was followed by quantitative RT-PCR. Formation of the NITEGE (ADAMTS-cleaved) and DIPEN (MMP-cleaved) aggrecan neoepitopes was detected by immunohistochemistry. While the expression of ADAMTS4, 9, 16 and furin was up-regulated during chondrogenesis, ADAMTS1 and 5 were down-regulated. Despite this regulation of ADAMTS, no formation of NITEGE neoepitopes occurred in MSC pellets, indicating no ADAMTS-induced cleavage of aggrecan. In contrast, MMP-induced cleavage of aggrecan appeared at 14 d after induction of chondrogenesis. Submission of differentiated MSC pellets to IL1β treatment for 3 d resulted in strong upregulation of ADAMTS1, 4 and 5, rapid proteoglycan depletion, and stimulation of ADAMTS-induced but not MMP-induced cleavage of aggrecan. Thus, there is no evidence for ADAMTS-induced aggrecan cleavage during chondrogenesis, but proteoglycan turnover is rapidly inducible under infl ammatory signals. Therapeutic aggrecanase inhibition for treatment of arthritic disease may thus not impede regenerative self-healing pathways based on chondrogenesis of local progenitor cells in the joint.
Introduction
Chondrogenesis is a process engaging differentiating cells into production of a large amount of extracellular matrix which fi lls the growing distance between them. This matrix is mainly composed of a network of collagen type II fi brils and of proteoglycans, among which aggrecan is predominant. Matrix homeostasis is ensured as chondrocytic cells synthesise matrix degrading enzymes such as matrix metalloproteases (MMPs) and enzymes from the "A Disintegrin And Metalloproteinase with ThromboSpondin motifs" protein family (ADAMTS). Matrix rearrangements by cleavage of collagen fi brils or aggrecan are expected to be particularly important during chondrogenesis, when the extracellular space is growing. The analysis of mouse models has indeed indicated that MMP function infl uences foetal cartilage development and specifi cally endochondral ossifi cation (Little and Fosang, 2010) . MMPs are strongly regulated during the chondrogenesis of human mesenchymal stem cells (MSCs) and we have shown previously that their inhibition prevents chondrogenic differentiation in vitro (Bertram et al., 2009) . This suggests that MMP activity is essential for chondrogenic differentiation of adult human MSCs. In contrast, the function of aggrecanases from the ADAMTS family does not appear to infl uence foetal cartilage development in mice (Little and Fosang, 2010) . Only a few data on the expression and activity of aggrecanases during chondrogenic differentiation of human MSCs are available so far. Expression profi les of the two main aggrecanases, ADAMTS4 and 5, in MSC pellets until 21 d of chondrogenesis suggested a regulation of both genes during this process, with the functional implications remaining unknown (Djouad et al., 2007) .
Loss of aggrecan is an early feature of cartilage degeneration in osteoarthritis (OA) (Aigner and McKenna, 2002) . Aggrecan can be cleaved by both MMPs and ADAMTS at different sites. However, it has been demonstrated that ADAMTS proteases and not MMPs are the major proteases responsible for aggrecan depletion during the progression of OA (Malfait et al., 2002; Sumer et al., 2007) . Inhibiting ADAMTS cleavage of the aggrecan interglobular domain improves restoration of cartilage aggrecan after its depletion in infl ammatory joint disease, while the inhibition of MMP cleavage does not . More particularly, it has been suggested that ADAMTS4 and 5, also known as aggrecanases 1 and 2, are the two major contributors to aggrecan depletion in humans (Song et al., 2007) while in mice ADAMTS5 appears to be the single enzyme involved 321 www.ecmjournal.org S Boeuf et al. Aggrecanases in chondrogenesis of MSCs (Stanton et al., 2005) . ADAMTS proteases, thus, play an essential role in matrix homeostasis of cartilage and, in the case of OA, in its destruction (Jones et al., 2005) . They have for this reason gained attention as potential therapeutic targets in OA (Fosang and Little, 2008) . In the context of therapeutic ADAMTS inhibition, it is of interest to examine the role these enzymes might play during in vitro chondrogenic differentiation of MSCs, since possible pathways of in vivo regeneration based on chondrogenesis of endogenous progenitor cells should not be impaired. While MMP inhibitors blocked in vitro chondrogenesis of human MSCs, it could be an advantage of aggrecanase inhibitors if their chondroprotective effect would not impair regeneration. The aim of this study therefore was to characterise the expression and activity of aggrecanases from the ADAMTS protein family during the chondrogenic differentiation of MSCs. The ADAMTS form a family of secreted proteases which include 19 human genes . Phylogenetic analysis identifi es closely related ADAMTS for which aggrecanase activity has been demonstrated. These include ADAMTS 1, 4, 5 and 8 . Aggrecanase activity has furthermore been demonstrated for the structurally less related ADAMTS9 and ADAMTS16 (Zeng et al., 2006) . Of these aggrecanases, all but one, ADAMTS8, have been shown to be expressed in cartilage (Kevorkian et al., 2004) . Therefore, the genes of ADAMTS1, 4, 5, 9 and 16 have been included in this study. Common to all ADAMTS is a signal peptide at the N terminus followed by a prodomain including at least one cleavage site for the proprotein peptidase furin. ADAMTS are expressed as zymogens and activated through furin cleavage either intracellularly in the endoplasmic reticulum (Longpre and Leduc, 2004; Wang et al., 2004) , at the cell surface (Koo et al., 2006) or extracellularly (Longpre et al., 2009) . For this reason, furin expression in MSCs was analysed in parallel.
Materials and Methods

Tissue samples
Human OA articular cartilage samples were obtained from 7 patients (age from 47 to 88) undergoing total knee replacement surgery. Healthy cartilage samples were obtained from the knees of 6 patients (age from 30 to 52) undergoing amputation for diseases not affecting the knee joint. Cartilage was carefully removed from the tibial plateau and femoral condyles, washed with phosphate buffered saline (PBS) to avoid contamination by other cells and snap-frozen in liquid nitrogen. Bone marrow samples for isolation of MSCs were obtained from 6 patients (age from 10 to 65) undergoing total hip replacement or iliac bone graft harvest. The studies were approved by the local ethics committee and informed consent was obtained from all individuals included in the study.
Isolation and expansion of MSCs
MSCs were isolated from fresh bone marrow samples as described previously (Haynesworth et al., 1992; Winter et al., 2003) . Briefl y, cells were fractionated on a FicollPaque Plus density gradient (GE Healthcare, Munich, Germany), and the low-density MSC-enriched fraction was washed and seeded in culture fl asks in an expansion medium (Reyes et al., 2001; Winter et al., 2003) consisting of DMEM high glucose, 40 % MCDB201, 2 % foetal calf serum (FCS), 2 x 10 -8 M dexamethasone, 10 -4 M ascorbic acid-2-phosphate, 10 μg/mL insulin, 10 μg/mL transferrin, 10 ng/mL sodium selenite, 100 units/mL penicillin, 100 μg/ mL streptomycin, 10 ng/mL recombinant epidermal growth factor (Miltenyi Biotec, Bergisch Gladbach, Germany) and 10 ng/mL platelet-derived growth factor BB (Active Bioscience, Hamburg, Germany). Non-adherent material was removed after 24-48 h. During expansion, medium was replaced twice a week. Cells were replated at 5 x 10 3 cells/cm 2 and used at passage 3.
Chondrogenic differentiation of MSCs and IL1β treatment
For induction of chondrogenesis at high cell density in three-dimensional culture, pellets consisting of 5 x 10 5 expanded MSCs were formed by centrifugation at 300 g (Eppendorf, Hamburg, Germany). Pellets were exposed to chondrogenic medium (DMEM high glucose with 0.1 μM dexamethasone, 0.17 mM ascorbic acid-2-phosphate, 5 μg/ mL insulin, 5 μg/mL transferrin, 5 ng/mL selenous acid, 1 mM sodium pyruvate, 0.35 mM proline, 1.25 mg/mL BSA, 100 units/mL penicillin and 100 μg/mL streptomycin) supplemented with 10 ng/mL recombinant human TGF-β1 (PeproTech, Hamburg, Germany) and cultivated for 6 weeks. Medium was changed every 2 to 3 d. After 42 d of chondrogenic induction, some pellets were maintained 3 additional days in chondrogenic medium without TGFβ ± 10 ng/mL IL1β (Promokine, Heidelberg, Germany). Medium was not changed during these 3 d. Quantitative RT-PCR mRNA was subjected to first strand cDNA synthesis using reverse transcriptase (Sensiscript, Qiagen, Hilden, Germany) and oligo-d(T) primers. Expression levels of individual genes were analysed by quantitative PCR (Lightcycler, Roche). Aliquots of fi rst-stranded cDNAs were amplifi ed using gene-specifi c primer sets (Table  1) obtained from Eurofi ns (Ebersberg, Germany) and real-time fl uorimetric intensity of SYBR green I was monitored. The Cycling parameters were optimised according to the Light-Cycler protocol from Roche (Light-Cycler Operator's Manual, Version 3.5, October 2000). The apparent threshold cycles (Ct) of the genes of interest were compared to the Ct of the housekeeping gene β-actin (ACTB) in the same cDNA sample. A standard curve based on diluted samples of ACTB cDNA was prepared by qPCR to deduce the e correlation factor between cDNA concentration and differences of Ct (ΔCt) of ACTB. Changes of ACTB concentration could be estimated as e^(0.5756 × ΔCt). This exponential function was then used to calculate fold differences between the gene of interest (Ct of the gene of interest, Ct-GO) and ACTB (Ct of ACTB, Ct-ACTB) in the same sample, which were converted as % of ACTB expression. The calculated expression level in % of ACTB was thus equal to:
All gene expression levels shown in fi gures and tables refer to relative levels in % of ACTB calculated with this formula. Melting curves and agarose gel electrophoresis of the PCR products were used for quality control.
Histology MSC Pellets were fixed in 4 % paraformaldehyde, as described (Hennig et al., 2007) . All samples were embedded in paraffi n. For visualisation of proteoglycans, 5 μm sections were stained with 2 g/L safranin O (Schmid. Köngen, Germany) and counterstained with fast green (Sigma-Aldrich, Seelze, Germany). Immunohistological staining for collagen type II was performed as described (Winter et al., 2003) . Briefl y, sections were incubated with a monoclonal mouse anti-human collagen II antibody (clone II-4C11; 1:1000; MP Biomedicals, Eschwege, Germany). Reactivity was detected using biotinylated goat anti-mouse antibody (Dianova, Hamburg, Germany), streptavidinalkaline phosphatase (Dako, Glostrup, Denmark), and fast red. Immunostaining for aggrecan neoepitopes generated by ADAMTS or MMP cleavage of the interglobular domain was done as previously described (Smith et al., 2008) . Briefl y, 5 μm paraffi n sections were rehydrated, digested with 0.1 units/mL protease-free chondroitinase ABC, (Sigma-Aldrich, Castle Hill, Australia) and 0.1 units/ mL of keratanase I (Sapphire Biosciences, Alexandria, Australia), prior to overnight incubation with primary antibodies to the aggrecanase-generated aggrecan neoepitope NITEGE (0.55 μg/mL; mAb Agg-C1; provided by Dr. Carl Flannery, Pfi zer Inc, Cambridge, MA, USA), and the MMP-generated aggrecan neoepitope DIPEN (0.17 μg/mL; affi nity-purifi ed polyclonal antisera; provided by Assoc. Prof Amanda Fosang, University of Melbourne, Melbourne, Australia). Equivalent concentrations of species-matched immunoglobulins on identically treated sections were used as a negative control.
Quantifi cation of proteoglycan content
Differentiated MSC pellets (2 or 3 per donor) were washed with PBS and mechanically crushed in 0.5 mL guanidine hydrochloride (GuHCl) extraction buffer (4 M GuHCl/100 mM Tris, pH 8.5). After incubation (30 min, 4 °C) and centrifugation (13000 rpm, 15 min, 4 °C), extracted proteoglycan in the supernatants was quantifi ed with alcian blue following Björnsson (1993) . In brief, chondroitin sulphate (3.125-200 μg/mL) was used as a standard. 50 μL SAT buffer (0.3 % H 2 SO 4 ; 0.75 % Triton X-100 in distilled H 2 O) was added to 100 μL supernatant before shaking for 15 min. Then, 750 μL alcian blue working solution (1 volume alcian blue stock solution (3 % (w/v) alcian blue (Carl Roth, Karlsruhe, Germany) in 0.1 % H 2 SO 4 , 0.4 M GuHCl) + 5 volumes SAT buffer + 9 volumes H 2 O) was added. After 30 min at room temperature under shaking, the precipitate was harvested by centrifugation (15 min, 13,000 rpm, RT) and the supernatant was discarded. The pellet was washed in 500 μL DMSO buffer (40 % DMSO; 0.05 M MgCl 2 in distilled H 2 O), kept at room temperature for 15 min, centrifuged (15 min, 20,000 g) and the supernatant was again discarded. In the following step the pellet was dissolved in 500 μL guanidine/propanol buffer (4 M GuHCl, 33 % n-propanol; 0.25 % Triton X-100). Two aliquots (200 μL) were transferred to 96 well fl at bottom plates and absorbance was measured at 650 nm. 
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Results
Upregulation of aggrecan during chondrogenic differentiation of MSCs
Chondrogenesis was induced in pellets of MSCs from 6 donors under supplementation with TGFβ1. As evidenced by immunohistological analysis for collagen type II and staining of proteoglycans with safranin O, fi rst accumulation of a cartilage-like matrix in part of the pellet was detected at day 14 (Fig. 1A) . The pellets of all donors showed similar patterns of collagen type II and proteoglycan accumulation and exhibited full chondrogenic differentiation after 42 d. The expression of COL2A1 and aggrecan (ACAN) mRNA increased to signifi cantly higher levels than at day 0 as early as the fi rst week of pellet culture in differentiation medium (Figs. 1C and D) . Thereafter, the expression of both COL2A1 and ACAN progressively increased from day 7 to 14 (24.8-fold, and 13.7-fold, respectively; p = 0.043 for both) and from day 14 to 28 (20.3-fold, and 3.13-fold, respectively; p = 0.043 for both). There was no further change in either COL2A1 or ACAN expression between day 28 and day 42. GAG content in MSC pellets was analysed for one donor and showed the expected up-regulation in accordance with safranin O staining which was lagging behind the up-regulation of ACAN gene expression (Fig. 1B ). Levels were increasing until day 35 and there was no further change between day 35 and 42.
Regulation of ADAMTS expression during chondrogenesis of MSCs
Gene expression levels of aggrecanases during chondrogenesis of MSCs were assessed by quantitative RT-PCR analysis of mRNA levels of ADAMTS1, 4, 5, 9 
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and 16, and of the proprotein peptidase furin at day 0, 4, 7, 14, 21, 28 and 42 after induction of chondrogenesis in MSC pellet cultures (n = 6). Furthermore, in order to compare expression levels detected in MSCs to physiological levels in cartilage, gene expression was determined in normal healthy cartilage samples from 6 donors and in OA cartilage samples from 7 donors ( Table 2) . The median gene expression of ADAMTS 1 in MSCs declined 10-fold over the period of 42 d of chondrogenic differentiation from 3.35 % in undifferentiated MSCs at day 0 to 0.33 % on day 42 ( Fig. 2A) . After stable gene expression levels comparable to expression in cartilage during the fi rst week, ADAMTS1 expression dropped between day 7 and 14 and thereafter remained at levels signifi cantly lower than at day 0 (p = 0.043). Among the other genes analysed, only ADAMTS5 showed a similar temporal change in expression profi le (Fig. 2B) , although ADAMTS5 was initially more than 8-fold lower expressed in undifferentiated MSCs than in normal cartilage (p = 0.002). A 3-fold drop of ADAMTS5 expression levels occurred between day 7 and 14, corresponding to a statistically signifi cant decline between day 0 and day 42 (p = 0.028). Remarkably, this decline occurred during the main shift of ACAN upregulation. In comparison to ADAMTS5, the other classical aggrecanase, ADAMTS4, showed a different regulation pattern (Fig. 2C) . Expression was low in undifferentiated MSCs and showed a more than 40-fold increase on day 4. After this transient peak, gene expression levels stabilised to levels close to expression in cartilage and signifi cantly higher than at day 0 (7-fold at day 42; p = 0.028). Similarly gene expression of ADAMTS9 was upregulated during chondrogenesis (Fig.  2D) , increasing signifi cantly from day 0 to day 42 (4-fold; p = 0.028), reaching levels not signifi cantly different from normal cartilage and very close to OA cartilage (Table 2) . ADAMTS16 was essentially not expressed in undifferentiated MSCs (levels lower than 0.01 % for all donors on day 0) and showed a signifi cant increase to 0.14 % after 14 d of chondrogenic differentiation compared to day 0 (p = 0.028) (Fig. 2E) . ADAMTS16 was the only aggrecanase with higher median expression levels in OA cartilage compared to normal cartilage, a difference which almost reached signifi cance (Table 2 ; p = 0.051), in agreement with previously published data (Kevorkian et al., 2004) . ADAMTS16 expression levels at day 42 after chondrogenesis were similar to OA cartilage and signifi cantly higher than in normal cartilage (5.5-fold; p = 0.009). The mRNA of the proprotein peptidase furin increased significantly from day 0 to day 7 of chondrogenesis (p = 0.043) (Fig. 2F) and reached a 4-fold increase after 42 d (p = 0.043). Furin showed a signifi cant 3.58-fold higher expression in OA cartilage compared to normal cartilage (p = 0.017), and at day 42 in pellet culture of MSCs, expression was similar to levels in normal cartilage and signifi cantly lower than in OA cartilage (2.14-fold; p = 0.004). ADAMTS4, 9, 16 and furin were thus all up-regulated during chondrogenesis of MSCs and reached levels comparable to OA cartilage (ADAMTS4, 9 and 16) or normal cartilage (ADAMTS4, 9 and furin) after differentiation. This indicates that these aggrecanases could possibly be activated during the differentiation process of MSCs when ACAN deposition is initiated.
Aggrecan proteolysis during the chondrogenesis of MSCs
In order to determine whether aggrecanase activity can be detected during chondrogenic differentiation of MSCs, an immunohistochemical analysis of ACAN neo-epitopes in MSC pellets was performed. Neo-epitopes occurring after cleavage of ACAN by ADAMTS (NITEGE epitope) or by MMPs (DIPEN epitope) were analysed in MSC pellets at day 14, 21, 28, 35, and 42 after induction of chondrogenesis (Fig. 3) . All ADAMTS analysed in this study have been shown to produce NITEGE neo-epitopes Zeng et al., 2006) . While the DIPEN neo-epitope was detected from day 14 and increased progressively during differentiation, no NITEGE neo-epitopes were apparent in MSC pellets at any time. This suggests that MMP cleavage but not ADAMTS cleavage of ACAN occurs at detectable levels during chondrogenic differentiation of MSCs.
Rapid loss of proteoglycan induced by IL1ß
While aggrecanases such as ADAMTS4, 9 and 16 were expressed in chondrogenic MSCs at similar levels to in cartilage, no ADAMTS-induced cleavage of ACAN was detected. In order to examine whether aggrecanase activity of ADAMTS is inducible in MSC pellets, the ADAMTS expression and activity was analysed in chondrogenic MSC pellets under an infl ammatory signal. MSC pellets after 42 d of chondrogenic induction were incubated for 3 d in the same medium deprived of TGFβ and supplemented with 10 ng/mL IL1β. The IL1β treatment induced a rapid and signifi cant loss of proteoglycan to 66 % of levels in control pellets (Figs. 4A and B) . While MMP-cleavage of ACAN was not changed after IL1β treatment, as seen by the unchanged DIPEN neo-epitope, ADAMTS cleavage of aggrecan was clearly induced by IL1β (Fig. 4A) . In parallel, IL1β led to a more than 3-fold decrease of gene expression levels of COL2A1 and ACAN (Fig. 4C) . Expression levels of ADAMTS1, 4 and 5 were signifi cantly up-regulated (4.9-fold; 5.2-fold and 9.4-fold respectively), while no signifi cant differences were found for ADAMTS9, 16 and furin (data not shown). Gene expression of ADAMTS1 and ADAMTS5 after IL1β treatment reached levels close to cartilage (3.22 % and 1.48 %, respectively).
Discussion
We have shown that the ADAMTS with known aggrecanase activity can be classifi ed in 2 groups showing different temporal expression patterns during chondrogenesis of S Boeuf et al.
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MSCs. ADAMTS1 and 5 were down-regulated during differentiation while ADAMTS4, 9 and 16 were upregulated. Interestingly, the 2 classical and most potent aggrecanases, ADAMTS4 and ADAMTS5, were classifi ed in 2 different groups. ADAMTS4, 9 and 16 showed low expression levels during expansion of MSCs and were up-regulated during chondrogenic differentiation, reaching levels equivalent to those in normal and OA cartilage for ADAMTS4 and 9, only to those in OA cartilage for ADAMTS16. The time point of the main shift of expression levels for ADAMTS9 and 16 was comparable to COL2A1 and ACAN, between day 7 and day 21 after induction of chondrogenesis. However, these two genes, albeit following a gene expression profi le similar to that of classical chondrogenic differentiation markers, showed low expression levels and no induction by IL1β in differentiated MSCs so that further analysis would be necessary to determine whether they play any role in chondrogenesis. Among the genes with up-regulated expression, the expression profi le of ADAMTS4 was unusual as it showed an early peak of very high expression levels after induction of chondrogenesis. Studies have suggested that TGFβ has a short term stimulatory effect on ADAMTS4 expression, which is not observed for other ADAMTS. This has been shown in synovial tissue and fi broblast-like synoviocytes (Yamanishi et al., 2002) as well as in prostatic cancer cells (Cross et al., 2005) . It is therefore possible that the expression peak at days 4 and 7 was due to the switch from a medium without TGFβ during expansion to a medium with TGFβ at day 0. However, other signalling pathways are activated early after induction of chondrogenesis and could also be involved in the specifi c regulation pattern of ADAMTS4. In a study where chondrogenesis was induced with a BMP2-containing conditioned medium, ADAMTS4 was one among few genes showing an upregulation of expression after 2 days (Djouad et al., 2007) . The ADAMTS4 up-regulation could thus be more generally linked to early chondrogenesis. We have shown previously that biglycan, COMP and decorin (Pelttari et al., 2006) which can be cleaved by ADAMTS4 (Melching et al., 2006; Kashigawa et al., 2004) are up-regulated as early as 2 d after induction of chondrogenesis in MSCs. Interestingly, all of these small proteoglycans modulate TGFβ signalling (Droguett et al., 2006; Ferdous et al., 2007; Haudenschild et al., 2011) . ADAMTS4 could, thus, be co-regulated with these molecules in an early phase of chondrogenesis as a part of a feedback loop modulating availability of growth factors to the cells.
On the other hand, ADAMTS1 and ADAMTS5 showed higher expression levels during expansion and adaptation of MSCs to pellet culture than during chondroblast formation and differentiation (Dexheimer et al., 2012) . Their down-regulation occurred during the main increase of ACAN expression between days 7 and 14. ADAMTS1 and 5 thus showed the highest expression levels during a phase when MSCs did not synthesise ACAN. This is in line with the detection of ADAMTS1 expression in the resting and proliferative zone of the growth plate of rats (Mitani et al., 2006) . The function of these aggrecanases during early phases of differentiation remains unclear and is intriguing, especially for ADAMTS1 which showed high expression levels, comparable to those in normal cartilage. The aggrecanolytic ADAMTS also have other proteoglycan substrates, such as versican and members of the small leucine repeat proteoglycan family, cleavage of which are known to play a role in development and tissue morphogenesis (reviewed in Stanton et al., 2011) . Whether the differential regulation of ADAMTS during MSC chondrogenesis is related to cleavage of proteoglycans other than aggrecan requires further investigation.
The chondrogenic induction of MSCs in vitro does not lead to the formation of articular-like chondrocytes but rather engages MSCs towards a hypertrophic differentiation stage characterised by the expression of markers such as collagen type X and MMP13 (Boeuf and Richter, 2010) . This raises the question on how far the hypertrophic character of this differentiation process could be involved in the regulation of ADAMTS expression. Runx2 is one of the main transcription factors regulating the expression of hypertrophy-associated genes (Solomon et al., 2008) and it strongly increased ADAMTS5 mRNA in human chondrosarcoma cells (Thirunavukkarasu et al., 2007) . Studies in mice and rats suggested increased expression or activity of ADAMTS1, 4 and 5 in the hypertrophic zone of growth plate cartilage Mitani et al., 2006; Groma et al., 2011) , while ADAMTS9 was expressed in the proliferating but not in the hypertrophic zone chondrocytes (Jungers et al., 2005) . This suggests that a hypertrophic phenotype is characterised by high expression of ADAMTS1, 4 and 5 and low ADAMTS9. The decrease with time of ADAMTS1 and 5 expression and the increase of ADAMTS9 expression during in vitro chondrogenesis of MSCs are thus not consistent with a full endochondral differentiation of MSCs, albeit data from human growth plate are not available.
The phenotype of OA chondrocytes has been compared with a hypertrophic phenotype (Dreier, 2010) , although the view of a generalised hypertrophy of OA chondrocytes is controversial . Of the genes up-regulated during chondrogenesis, ADAMTS9 and ADAMTS16 reached expression levels closer to OA cartilage at day 4, while expression was closer to normal cartilage for furin. Globally, the expression profi le of the MSC pellets at day 42 cannot be classifi ed as being closer to the normal or OA phenotypes of chondrocytes. Actually, differences of ADAMTS mRNA expression between OA and normal cartilage did not reach signifi cance in our study, although it was almost the case for ADAMTS16 (5-fold higher in OA, p = 0.051), in accordance with previous data (Kevorkian et al., 2004) . Our study does, however, not support signifi cantly lower ADAMTS1 levels in OA (Kevorkian et al., 2004) , nor signifi cantly higher expression of both ADAMTS4 and 5 in late but not early OA (Bau et al., 2002) . Overall, data point out that ADAMTS expression may vary during the progression of the disease and that this may partly explain the divergent expression levels found in cartilage.
Although ADAMTS4, 9 and 16 were up-regulated during chondrogenesis, ADAMTS-induced cleavage of ACAN was not detectable during differentiation. Possibly S Boeuf et al. Aggrecanases in chondrogenesis of MSCs ADAMTS activity is not required for proper differentiation but inactive proteins are produced and stored in the extracellular cartilage matrix for quick access in case of challenge. Indeed, exposure of pellets to IL1ß was able to rapidly induce aggrecanase enzyme activity, confi rming that all required constituents to induce proteoglycan depletion are available. In contrast, MMP-induced cleavage of ACAN was detected without any further challenge and was found to occur as soon as MSC pellets initiate deposition of ACAN in the matrix. This is similar to what has been observed in normal juvenile cartilage, where MMP-cleaved, but not ADAMTS-cleaved, ACAN was found (Little et al., 1999) . This suggests that ADAMTSinduced cleavage of ACAN may not be implicated in chondrogenic differentiation and that therefore the chondroprotective effect of aggrecanase inhibitors may not be associated with negative effects on chondrogenic and regenerative processes. It has indeed been shown that the inhibition of ADAMTS-induced cleavage of ACAN improves restoration of cartilage ACAN after its depletion in infl ammatory joint disease . In contrast, the inhibition of MMP-induced cleavage of ACAN did not allow cartilage regeneration and resulted in signifi cantly worse cartilage damage in a surgical OA model . This suggests that MMPinduced cleavage of ACAN may be protective in OA, which could be related to the essential function of MMPs during chondrogenesis (Bertram et al., 2009) . Importantly, aggrecanase inhibition could have the advantage to allow a chondroprotective intervention which does not interfere with cartilage regeneration. Exposure of MSC pellets to infl ammatory conditions stimulated ADAMTS-induced cleavage of ACAN while MMP-cleaved ACAN was not affected. In terms of cleavage of ACAN, MSC pellets thus behave in a similar way to normal young articular cartilage (Little et al., 1999) . IL1β induced an up-regulation of ADAMTS1, 4 and 5 and a down-regulation of COL2A1 and ACAN expression. The down-regulation of extracellular matrix genes by IL1β treatment is in line with observations for articular chondrocytes (Fan et al., 2005) and the known inhibitory activity of IL1β on in vitro chondrogenesis of MSCs (Felka et al., 2009) . On the other hand, our data show that activation of ADAMTS by IL1β treatment could be partially due to transcriptional regulation of the aggrecanases, especially as these include the 2 classical human aggrecanases thought to be the major contributors to ACAN depletion in humans (Song et al., 2007) . Interestingly, ADAMTS4 and 5 showed very different patterns of gene expression during chondrogenesis of MSCs, but IL1β treatment resulted in a marked induction of the expression of both genes. This is different from what has been reported for human articular cartilage or articular chondrocytes, where in most studies IL1β was found to induce expression of ADAMTS4 but not ADAMTS5 . Thus, while ADAMTS4 appears to be expressed in differentiated MSCs at similar levels as in cartilage and to be inducible under identical conditions, ADAMTS5 expression and inducibility in MSCs differed from articular cartilage.
Conclusions
In summary, we have shown that although MSCs induce the expression of the genes for ADAMTS4, 9 and 16 during chondrogenesis, no ADAMTS-induced cleavage of ACAN but rather an MMP mediated neoepitope formation occurs. ADAMTS-induced cleavage can however be stimulated by an infl ammatory signal in chondrogenic MSCs like in articular cartilage. ADAMTS-induced cleavage of ACAN, thus, appears not to be critical for chondrogenic differentiation of MSCs, while it plays an essential role for ACAN depletion upon infl ammatory signals. These results suggest that aggrecanase inhibition could be benefi cial in degenerative diseases, not only based on its protective effects on the matrix but also because it does not interfere with chondrogenesis, and thus may allow regenerative processes based on endogenous progenitor cells to take place.
